Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Down 44.0% in May

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was the recipient of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 4,200 shares, a decrease of 44.0% from the April 30th total of 7,500 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 236,800 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, HC Wainwright raised their price objective on shares of Armata Pharmaceuticals from $7.00 to $9.00 and gave the company a "buy" rating in a research report on Monday, May 19th.

Armata Pharmaceuticals Price Performance

ARMP stock traded up $0.07 during trading on Wednesday, hitting $2.00. 10,569 shares of the company traded hands, compared to its average volume of 69,067. The stock has a 50-day moving average of $1.47. Armata Pharmaceuticals has a 1 year low of $0.90 and a 1 year high of $3.42. The firm has a market capitalization of $72.50 million, a price-to-earnings ratio of -1.22 and a beta of 0.87.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.